Dr Lal PathLabs subsidiary completes 30 percent stake buy in Neuome Technologies

Listed-company acquisitionStrategic Transactions View source PDF Explain this filing

LALPATHLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.9%Reaction day

₹1944.00

prior close

₹1938.50

announcement price

After-mkt

timing

Nifty Smallcap 250market+0.3%-1.2% vs market

Healthcare Service Provider peers, median of 29sector+0.7%-1.6% vs sector

On the reaction day the stock moved 1.2 pts less than Nifty Smallcap 250 and 1.6 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.9+0.3-1.2+0.7-1.6

Next day

+0.7-0.3+1.0+0.2+0.5

-2.0-0.4-1.6+1.0-3.0

-1.5-1.0-0.5+0.5-2.0

-0.9+0.1-0.9+0.7-1.6

-2.8+0.3-3.0+1.0-3.8

-2.1+0.5-2.6+1.2-3.3

15d

-1.4-0.8-0.5+0.5-1.9

+0.8-3.1+3.9-0.7+1.5

-1.1-7.8+6.7-8.3+7.2

—————

UpDownMarket · Nifty Smallcap 250Sector · Healthcare Service Provider peers, median of 29Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dr Lal PathLabs wholly owned subsidiary Dr Lal Ventures has completed the subscription of a 30 percent stake in Neuome Technologies Private Limited on August 27, 2026. The deal was originally approved by the subsidiary board on July 24, 2026. With completion, Neuome has now become an associate company of Dr Lal PathLabs. This is an update to the prior intimation and finalises the investment.

Likely market impact

Neuome becomes an associate company, adding a minority strategic investment to the group. Limited immediate financial impact, but signals expansion into a related tech or diagnostics venture.